Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
(2014) Journal of Rheumatology — Vol. 41, n° 4, p. 629-639 (2014)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 1.4 MB
Details
- Authors
- Abstract
- Assess longterm tolerability, safety, and efficacy of subcutaneous (SC) abatacept (ABA) in methotrexate-refractory patients with rheumatoid arthritis (RA).
- Affiliations
Citations
Genovese, M. C., Tena, C. P., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon-Campos, J. A., Box, J., Legerton, C. W., Nasonov, E., Durez, P., Delaet, I., Teng, J., & Alten, R. (2014). Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. Journal of Rheumatology, 41(4), 629-639. https://doi.org/10.3899/jrheum.130112 (Original work published 2014)